Navigation Links
Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
Date:2/26/2013

tralia. La reclutación de pacientes comenzó en junio de 2012. Los sujetos son pacientes con cáncer colorrectal no reseccionable, avanzado y recurrente que rechaza las quimioterapias estándares (fluoropirimidina, irinotecan, oxaliplatin, bevacizumab, y anticuerpo monoclonal EGFR en casos de tumor de tipo no mutado KRAS). El ensayo comparará a los pacientes aleatoriamente asignados para recibir TAS-102 o placebo para investigar la eficacia y seguridad de TAS-102. La medida de evaluación principal es la supervivencia general. Los principales investigadores son el doctor Atsushi Otsu , director del Clinical Development Center del National Cancer Center Hospital East (Japón), el doctor Robert J. Mayer del Dana Farber Cancer Institute (USA), y el doctor Eric Van Cutsem del University Hospital Gasthuisberg (Bélgica).

Acerca de Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, una filial de Otsuka Holdings Co., Ltd. (http://www.otsuka.com/en/), es una compañía farmacéutica de I+D centrada en los tres campos de oncología, alergias e inmunología, y urología. Su filosofía corporativa es una promesa: "Nos esforzamos por mejorar la salud humana y contribuir al enriquecimiento de la sociedad." En particular, en el campo de la oncología, Taiho Pharmaceutical es conocida como una compañía líder en Japón y en todo el mundo por el desarrollo de medicinas basadas en la evidencia para el tratamiento del cáncer. Además, en otras áreas distintas a la oncología, la compañía crea productos de calidad que tratan las enfermedades médicas de forma efectiva y pueden ayudar a mejorar la calidad de vida de las personas. Poniendo siempre al cliente en primer lugar, Taiho Pharmaceutical también pretende ofrecer productos médicos de
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
3. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
9. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
10. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
11. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:7/10/2014)... 10, 2014 CVS Caremark Corporation (NYSE: ... approved a quarterly dividend of $0.275 (27.5 cents) per share ... August 1, 2014, to holders of record on July 21, ... Caremark is dedicated to helping people on their path to ... the United States . Through the company,s more ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... 20, 2012  NxStage Medical, Inc. (Nasdaq: NXTM ... announced plans to release its financial results for the ... on Wednesday, February 29, 2012  before the opening of ... ) NxStage will also host a conference ...
... 2012  INVO Bioscience, Inc. (OTC BB: IVOB), a medical ... with infertility, today announced that the National Health Surveillance ... INVOcell for use as a Class II device. This ... of infertile couples in Brazil and marks a major ...
Cached Medicine Technology:NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results 2INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA 2INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA 3
(Date:7/12/2014)... SATURDAY, July 12, 2014 (HealthDay News) -- If you make ... contends. In one experiment, 56 adults were led on ... an exercise walk or a scenic walk. The participants were ... it was an exercise outing ate 35 percent more chocolate ... a scenic walk. In another experiment, 46 adults were ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Using ... so one of two inventors from Ashland, Va., decided ... do this. "This inspired us to conceive of our ... of the patent-pending KIDNEY KOVER, which provides an inconspicuous ... It avoids embarrassment, as well as promotes comfort and ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
(Date:7/12/2014)... West Palm Beach, FL (PRWEB) July 12, 2014 ... wide variety of high-quality peptides that are used solely ... online. To honor two successful years in business, Maxim ... Performance LLC, has just launched a new and updated ... addition, the research blog section has been updated with ...
Breaking Medicine News(10 mins):Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2
... Macmillan Cancer Support of UK has taken a strong campaign ... that in Scotland people spent// an average of ?636 on ... in Wales. ,The demand of the charity is ... ,"These regional variations are shocking and grossly unfair - cancer ...
... to heart abnormalities, is apparently safe to use in ... yesterday//. The researchers said that they found no ... their pregnancies fearing that the drug could affect their ... studied 119 women treated with Seroxat for six years ...
... suffering, a tuberculosis (TB) patient in Madhya Pradesh has requested Indian ... life and that of his four minor children. ... late 40s, is suffering from TB and has long been dependent ... of TB a few years ago. ,He has now ...
... chemical compound found in cannabis, also known as hashish ... after testing it on rats //. ,Yehoshua ... Israel, has created a synthetic version of a minor ... help in lowering blood pressure, reported science portal The ...
... a common school system in the country, educationists Sunday ... primary education //system and remove disparities among students. ... system in the country so that all students get ... said Madhu Prasad, educationist and a professor in Delhi ...
... Administration borrowed data from the 2004 National Survey on ... persons, 12 years of age or older, made ... to the survey. Meanwhile, an estimated 2.1 million Americans ... cocaine abuse. ,The statistics revealed the following ...
Cached Medicine News:
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... AvantGard Low Binding 0.5l - 10l Eppendorf ... binding technology that significantly reduces the amount of ... other filter tips are advertised as low retention, ... adhering to the pipet tip. However, AvantGard also ...
10 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 2, 5 and 10 L pipettes....
Medicine Products: